Poor prognosis of nucleophosmin overexpression in solid tumors: a meta-analysis

[1]  Mohammed A. Ismael,et al.  The Targeting of RNA Polymerase I Transcription Using CX-5461 in Combination with Radiation Enhances Tumour Cell Killing Effects in Human Solid Cancers , 2019, Cancers.

[2]  K. Nagata,et al.  Efficient DNA binding of NF-κB requires the chaperone-like function of NPM1 , 2016, Nucleic acids research.

[3]  Bai Zhao,et al.  High expression of B23 is associated with tumorigenesis and poor prognosis in bladder urothelial carcinoma , 2016, Molecular medicine reports.

[4]  L. Yue,et al.  Both high expression of nucleophosmin/B23 and CRM1 predicts poorer prognosis in human gastric cancer , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[5]  L. Federici,et al.  Molecules that target nucleophosmin for cancer treatment: an update , 2016, Oncotarget.

[6]  M. Lindström,et al.  NPM1 histone chaperone is upregulated in glioblastoma to promote cell survival and maintain nucleolar shape , 2015, Scientific Reports.

[7]  Q. Lan,et al.  Upregulation of B23 promotes tumor cell proliferation and predicts poor prognosis in glioma. , 2015, Biochemical and biophysical research communications.

[8]  Minmin Shi,et al.  NPM1 activates metabolic changes by inhibiting FBP1 while promoting the tumorigenicity of pancreatic cancer cells , 2015, Oncotarget.

[9]  C. Chai,et al.  Nucleophosmin overexpression is associated with poor survival in astrocytoma , 2015, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[10]  Jie Shen,et al.  Estrogen mediated expression of nucleophosmin 1 in human endometrial carcinoma clinical stages through estrogen receptor-α signaling , 2014, Cancer Cell International.

[11]  Yong Li,et al.  Prognostic significance of the co-expression of nucleophosmin and trefoil factor 3 in postoperative gastric cancer patients. , 2014, Molecular and clinical oncology.

[12]  Dong-hui Xu,et al.  Regulatory role of nucleophosmin during the differentiation of human liver cancer cells. , 2014, International journal of oncology.

[13]  Diana M. Mitrea,et al.  Structural polymorphism in the N-terminal oligomerization domain of NPM1 , 2014, Proceedings of the National Academy of Sciences.

[14]  C. Vascotto,et al.  Expression and prognostic significance of APE1/Ref-1 and NPM1 proteins in high-grade ovarian serous cancer. , 2014, American journal of clinical pathology.

[15]  S. Hsieh,et al.  A novel interaction of nucleophosmin with BCL2‐associated X protein regulating death evasion and drug sensitivity in human hepatoma cells , 2013, Hepatology.

[16]  S. Hsueh,et al.  Estrogen stimulates the proliferation of human endometrial cancer cells by stabilizing nucleophosmin/B23 (NPM/B23) , 2013, Journal of Molecular Medicine.

[17]  Hua Guo,et al.  Expression of Nucleophosmin/NPM1 correlates with migration and invasiveness of colon cancer cells , 2012, Journal of Biomedical Science.

[18]  F. Cakalagaoglu,et al.  Nucleophosmin expression in renal cell carcinoma and oncocytoma , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[19]  I. Nishimoto,et al.  Nucleophosmin, p53, and Ki-67 expression patterns on an oral squamous cell carcinoma tissue microarray. , 2010, Human pathology.

[20]  A. Stang.  Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.

[21]  G. Tell,et al.  Nucleophosmin is overexpressed in thyroid tumors. , 2010, Biochemical and biophysical research communications.

[22]  S. Hirohashi,et al.  Nucleophosmin as a Candidate Prognostic Biomarker of Ewing's Sarcoma Revealed by Proteomics , 2009, Clinical Cancer Research.

[23]  M. Olson,et al.  Nucleolar protein B23 has molecular chaperone activities , 2008, Protein science : a publication of the Protein Society.

[24]  David N. Boone,et al.  Nucleophosmin interacts directly with c-Myc and controls c-Myc-induced hyperproliferation and transformation , 2008, Proceedings of the National Academy of Sciences.

[25]  B. Yung.  Oncogenic role of nucleophosmin/B23. , 2007, Chang Gung medical journal.

[26]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[27]  Brunangelo Falini,et al.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. , 2007, Blood.

[28]  Pier Paolo Pandolfi,et al.  Nucleophosmin and cancer , 2006, Nature Reviews Cancer.

[29]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[30]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[31]  M. Okuda.  The role of nucleophosmin in centrosome duplication , 2002, Oncogene.

[32]  H. F. Horn,et al.  Nucleophosmin/B23 Is a Target of CDK2/Cyclin E in Centrosome Duplication , 2000, Cell.

[33]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[34]  J. Rüschoff,et al.  In vitro and ex vivo expression of nucleolar proteins B23 and p120 in benign and malignant epithelial lesions of the prostate. , 1995, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[35]  C. Lehner,et al.  Major nucleolar proteins shuttle between nucleus and cytoplasm , 1989, Cell.

[36]  B. Yung,et al.  Identification and characterization of a hexameric form of nucleolar phosphoprotein B23. , 1987, Biochimica et biophysica acta.

[37]  Yan-Fang Xie,et al.  Prognostic role of nucleophosmin in colorectal carcinomas. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[38]  X. Wang,et al.  Nucleophosmin and human cancer. , 2006, Cancer detection and prevention.